ES2555160B1 - Aptámeros específicos de TLR-4 y usos de los mismos - Google Patents

Aptámeros específicos de TLR-4 y usos de los mismos Download PDF

Info

Publication number
ES2555160B1
ES2555160B1 ES201430955A ES201430955A ES2555160B1 ES 2555160 B1 ES2555160 B1 ES 2555160B1 ES 201430955 A ES201430955 A ES 201430955A ES 201430955 A ES201430955 A ES 201430955A ES 2555160 B1 ES2555160 B1 ES 2555160B1
Authority
ES
Spain
Prior art keywords
tlr
aptamer
seq
complex
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201430955A
Other languages
English (en)
Spanish (es)
Other versions
ES2555160A1 (es
Inventor
Ignacio LIZASOAIN HERNÁNDEZ
Víctor Manuel González Muñoz
Gerónimo Fernández Gómez-Chacón
María Ángeles MORO SÁNCHEZ
María Elena Martín Palma
Ana MORAGA YÉBENES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptatargets SL
Original Assignee
Aptus Biotech S L
Aptus Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201430955A priority Critical patent/ES2555160B1/es
Application filed by Aptus Biotech S L, Aptus Biotech SL filed Critical Aptus Biotech S L
Priority to PCT/EP2015/064277 priority patent/WO2015197706A1/en
Priority to PL15732619T priority patent/PL3161139T3/pl
Priority to US15/322,021 priority patent/US10196642B2/en
Priority to BR112016030172-2A priority patent/BR112016030172B1/pt
Priority to ES15732619T priority patent/ES2825106T3/es
Priority to KR1020177001493A priority patent/KR102454682B1/ko
Priority to MX2016016992A priority patent/MX387405B/es
Priority to RU2016152094A priority patent/RU2709718C9/ru
Priority to PT157326190T priority patent/PT3161139T/pt
Priority to CN201580034070.1A priority patent/CN106459980B/zh
Priority to JP2016575345A priority patent/JP6959738B2/ja
Priority to SI201531392T priority patent/SI3161139T1/sl
Priority to CN202010953057.9A priority patent/CN112111495A/zh
Priority to AU2015279248A priority patent/AU2015279248B2/en
Priority to DK15732619.0T priority patent/DK3161139T3/da
Priority to MA040283A priority patent/MA40283A/fr
Priority to CA2953020A priority patent/CA2953020C/en
Priority to EP15732619.0A priority patent/EP3161139B1/en
Publication of ES2555160A1 publication Critical patent/ES2555160A1/es
Application granted granted Critical
Publication of ES2555160B1 publication Critical patent/ES2555160B1/es
Priority to ZA2017/00363A priority patent/ZA201700363B/en
Priority to US16/220,726 priority patent/US10808252B2/en
Priority to JP2020082070A priority patent/JP2020127422A/ja
Priority to US17/022,984 priority patent/US11591603B2/en
Priority to US18/156,936 priority patent/US12655435B2/en
Priority to US19/646,703 priority patent/US20260218204A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
ES201430955A 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos Expired - Fee Related ES2555160B1 (es)

Priority Applications (25)

Application Number Priority Date Filing Date Title
ES201430955A ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos
DK15732619.0T DK3161139T3 (da) 2014-06-24 2015-06-24 Tlr-4-specifikke aptamerer og anvendelser heraf
US15/322,021 US10196642B2 (en) 2014-06-24 2015-06-24 Aptamers specific for TLR-4 and uses thereof
BR112016030172-2A BR112016030172B1 (pt) 2014-06-24 2015-06-24 Aptâmeros específicos para tlr-4 e usos dos mesmos
ES15732619T ES2825106T3 (es) 2014-06-24 2015-06-24 Aptámeros específicos para TLR-4 y usos de los mismos
KR1020177001493A KR102454682B1 (ko) 2014-06-24 2015-06-24 Tlr-4에 특이적인 압타머 및 이의 용도
MX2016016992A MX387405B (es) 2014-06-24 2015-06-24 Aptámeros específicos de tlr-4 y usos de los mismos.
RU2016152094A RU2709718C9 (ru) 2014-06-24 2015-06-24 Аптамеры, специфические в отношении tlr-4, и их применение
PT157326190T PT3161139T (pt) 2014-06-24 2015-06-24 Aptâmeros específicos para tlr-4 e usos dos mesmos
CN201580034070.1A CN106459980B (zh) 2014-06-24 2015-06-24 Tlr-4特异性适配体及其应用
JP2016575345A JP6959738B2 (ja) 2014-06-24 2015-06-24 Ｔｌｒ−４特異的アプタマーおよびそれらの使用
PL15732619T PL3161139T3 (pl) 2014-06-24 2015-06-24 Aptamery swoiste wobec tlr-4 oraz ich zastosowania
PCT/EP2015/064277 WO2015197706A1 (en) 2014-06-24 2015-06-24 Aptamers specific for tlr-4 and uses thereof
AU2015279248A AU2015279248B2 (en) 2014-06-24 2015-06-24 Aptamers specific for TLR-4 and uses thereof
CA2953020A CA2953020C (en) 2014-06-24 2015-06-24 Aptamers specific for tlr-4 and uses thereof
SI201531392T SI3161139T1 (sl) 2014-06-24 2015-06-24 Aptameri, specifični za TLR-4 in njihove uporabe
MA040283A MA40283A (fr) 2014-06-24 2015-06-24 Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
EP15732619.0A EP3161139B1 (en) 2014-06-24 2015-06-24 Aptamers specific for tlr-4 and uses thereof
CN202010953057.9A CN112111495A (zh) 2014-06-24 2015-06-24 Tlr-4特异性适配体及其应用
ZA2017/00363A ZA201700363B (en) 2014-06-24 2017-01-17 Aptamers specific for tlr-4 and uses thereof
US16/220,726 US10808252B2 (en) 2014-06-24 2018-12-14 Aptamers specific for TLR-4 and uses thereof
JP2020082070A JP2020127422A (ja) 2014-06-24 2020-05-07 Ｔｌｒ−４特異的アプタマーおよびそれらの使用
US17/022,984 US11591603B2 (en) 2014-06-24 2020-09-16 Aptamers specific for TLR-4 and uses thereof
US18/156,936 US12655435B2 (en) 2014-06-24 2023-01-19 Aptamers specific for TLR-4 and uses thereof
US19/646,703 US20260218204A1 (en) 2014-06-24 2026-04-14 Aptamers specific for tlr-4 and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430955A ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos

Publications (2)

Publication Number Publication Date
ES2555160A1 ES2555160A1 (es) 2015-12-29
ES2555160B1 true ES2555160B1 (es) 2016-10-25

Family

ID=53496661

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430955A Expired - Fee Related ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos
ES15732619T Active ES2825106T3 (es) 2014-06-24 2015-06-24 Aptámeros específicos para TLR-4 y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15732619T Active ES2825106T3 (es) 2014-06-24 2015-06-24 Aptámeros específicos para TLR-4 y usos de los mismos

Country Status (18)

Country Link
US (5) US10196642B2 (enExample)
EP (1) EP3161139B1 (enExample)
JP (2) JP6959738B2 (enExample)
KR (1) KR102454682B1 (enExample)
CN (2) CN106459980B (enExample)
AU (1) AU2015279248B2 (enExample)
BR (1) BR112016030172B1 (enExample)
CA (1) CA2953020C (enExample)
DK (1) DK3161139T3 (enExample)
ES (2) ES2555160B1 (enExample)
MA (1) MA40283A (enExample)
MX (1) MX387405B (enExample)
PL (1) PL3161139T3 (enExample)
PT (1) PT3161139T (enExample)
RU (1) RU2709718C9 (enExample)
SI (1) SI3161139T1 (enExample)
WO (1) WO2015197706A1 (enExample)
ZA (1) ZA201700363B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709776B2 (en) * 2014-04-07 2020-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing outer membrane vesicles
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3494994A1 (en) * 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN113423833B (zh) * 2018-09-28 2024-09-17 奥曼尼提纳米有限公司 用于选择功能性适体的方法和组合物
US20210322575A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
WO2020069565A1 (en) 2018-10-02 2020-04-09 WearOptimo Pty Ltd Measurement system
US12569679B2 (en) 2018-10-02 2026-03-10 WearOptimo Pty Ltd Treatment delivery system
US12484814B2 (en) 2018-10-02 2025-12-02 WearOptimo Pty Ltd Actuator system
AU2020276703A1 (en) * 2019-05-16 2021-12-09 Merck Patent Gmbh Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
WO2021257494A1 (en) * 2020-06-15 2021-12-23 President And Fellows Of Harvard College Methods for modulating tlr4 signaling
CN114152599B (zh) * 2021-12-01 2023-10-13 中国农业大学 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器
CN114836425A (zh) * 2022-02-25 2022-08-02 温州医科大学附属眼视光医院 检测小胶质细胞的核酸适体及应用
US20260218202A1 (en) 2023-01-05 2026-07-30 Merck Patent Gmbh Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
WO2024240750A1 (en) 2023-05-22 2024-11-28 Aptatargets, S.L. New tlr-4 antagonist aptamers

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US248517A (en) 1881-10-18 Apparatus for transferring wood-graining
US690786A (en) 1901-09-21 1902-01-07 Andrew Stenger Bung.
US763130A (en) 1903-09-05 1904-06-21 Paul Walther Composition for artificial stone.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH088933B2 (ja) 1987-07-10 1996-01-31 日本ゼオン株式会社 カテ−テル
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
WO1992005186A1 (en) 1990-09-20 1992-04-02 Gilead Sciences Modified internucleoside linkages
JPH117658A (ja) 1997-04-25 1999-01-12 Sony Corp 光学記録媒体及び光学ディスク装置
WO2001057259A1 (en) * 2000-02-03 2001-08-09 Research Development Foundation Signaling aptamers that transduce molecular recognition to a differential signal
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
CN101227922A (zh) * 2005-05-06 2008-07-23 斯克里普斯研究学院 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
EP1997902B1 (en) * 2006-03-30 2013-09-18 Hiroshima University Screening method
EA201100811A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
US9012410B2 (en) * 2006-12-13 2015-04-21 Case Western Reserve University Method of treating intrauterine inflammation
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
AU2008285626B2 (en) 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
EP2365814A1 (en) * 2008-11-04 2011-09-21 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 4 expression by antisense oligonucleotides
WO2010060030A1 (en) 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
WO2012038851A1 (en) 2010-09-24 2012-03-29 Pfizer Inc. Isoxazoline oximes as antiparasitic agents
AU2012223366B2 (en) * 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2681314B1 (en) * 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
AU2020276703A1 (en) 2019-05-16 2021-12-09 Merck Patent Gmbh Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4
US20260218202A1 (en) 2023-01-05 2026-07-30 Merck Patent Gmbh Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
WO2024240750A1 (en) 2023-05-22 2024-11-28 Aptatargets, S.L. New tlr-4 antagonist aptamers

Also Published As

Publication number Publication date
SI3161139T1 (sl) 2020-12-31
CN106459980B (zh) 2020-11-03
CN112111495A (zh) 2020-12-22
US12655435B2 (en) 2026-06-16
EP3161139B1 (en) 2020-07-22
MX387405B (es) 2025-03-18
US11591603B2 (en) 2023-02-28
US10196642B2 (en) 2019-02-05
BR112016030172B1 (pt) 2022-11-01
RU2709718C9 (ru) 2020-02-06
RU2016152094A3 (enExample) 2019-01-29
US10808252B2 (en) 2020-10-20
PL3161139T3 (pl) 2021-01-11
MA40283A (fr) 2017-05-03
WO2015197706A1 (en) 2015-12-30
ZA201700363B (en) 2018-11-28
MX2016016992A (es) 2017-05-03
KR102454682B1 (ko) 2022-10-13
US20170130227A1 (en) 2017-05-11
US20230279402A1 (en) 2023-09-07
KR20170021298A (ko) 2017-02-27
CA2953020A1 (en) 2015-12-30
JP6959738B2 (ja) 2021-11-05
JP2017527260A (ja) 2017-09-21
AU2015279248A1 (en) 2017-01-12
EP3161139A1 (en) 2017-05-03
DK3161139T3 (da) 2020-10-19
RU2709718C2 (ru) 2019-12-19
RU2016152094A (ru) 2018-07-26
BR112016030172A2 (pt) 2017-11-14
ES2555160A1 (es) 2015-12-29
JP2020127422A (ja) 2020-08-27
US20210130830A1 (en) 2021-05-06
PT3161139T (pt) 2020-10-23
ES2825106T3 (es) 2021-05-14
US20190211334A1 (en) 2019-07-11
CN106459980A (zh) 2017-02-22
US20260218204A1 (en) 2026-07-30
CA2953020C (en) 2023-01-10
AU2015279248B2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
ES2555160A1 (es) Aptámeros específicos de TLR-4 y usos de los mismos
Wang et al. A targeted exosome therapeutic confers both CfDNA scavenging and macrophage polarization for ameliorating rheumatoid arthritis
JP6882782B2 (ja) 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US20210000981A1 (en) Conjugated polycationic polymers, methods of using the same and methods of treating autoimmune diseases, infectious diseases and acute radiation exposure
WO2013186857A1 (ja) Ｆｇｆ２に対するアプタマー及びその使用
KR20170132234A (ko) 혈관 내피 증식 인자 수용체에 결합하는 핵산 앱타머
US10760083B2 (en) DNA aptamer that binds to vWF
JP2022533966A (ja) Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
ES2731232T3 (es) Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio
US20190071675A1 (en) Inhibitors of dek protein and related methods
JP2021521806A (ja) Ｔｎｆ関連炎症性疾患を治療または診断するｔｎｆ指向性アプタマーおよびその使用
JPWO2009063998A1 (ja) 疎水性物質付加核酸及びその使用
JP6249453B2 (ja) Ｉｌ−１７に対するアプタマー及びその使用
HK1240610A1 (en) Aptamers specific for tlr-4 and uses thereof
HK1240610B (en) Aptamers specific for tlr-4 and uses thereof
Moreno Exploring the Interface Between Therapeutically Relevant Polymers
JP2011045339A (ja) ＴＧＦ−βＩＩ型受容体に結合する核酸およびその使用

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2555160

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20161025

PC2A Transfer of patent

Owner name: APTATARGETS, S.L.

Effective date: 20171128

FD2A Announcement of lapse in spain

Effective date: 20220727